Pasithea
Therapeutics Announces Collaboration with The Glimpse
Group
- The Glimpse Group is a Virtual Reality and Augmented
Reality platform company
- Partnership will allow Pasithea to co-develop VR
environments for patients with psychiatric disorders
Miami Beach, FL / March 8, 2022 -- InvestorsHub NewsWire
-- Pasithea Therapeutics
Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced its partnership with The Glimpse Group,
Inc. (Nasdaq:VRAR, FSE:9DR) ("Glimpse"), a Virtual Reality and
Augmented Reality ("VR and AR") platform company and its subsidiary
company Foretell Reality. Foretell Reality
applies VR technology to various use cases of mental health
therapy, support, and human interaction.
"We are thrilled to partner with Glimpse to bring VR and AR
to patients suffering from mental health disorders. Among its many
benefits, VR unites a patient and therapist in a shared
environment, which is particularly important in situations where
the therapist is remote, such as with our at-home treatment model.
VR can also create scenarios to reflect specific traumatic
experiences or simulate emotionally loaded conversations. VR is
increasingly becoming an innovative clinical tool for patients with
specific psychiatric symptoms, which leads to improved patient
outcomes, and we look forward to co-developing the program
alongside Glimpse," stated Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics.
Together with Glimpse, Pasithea will co-develop VR
environments to support the treatment of patients with psychiatric
disorders in a safe and effective manner.
Lyron Bentovim, President and CEO of Glimpse commented, "VR
technology is becoming widely adopted in the healthcare industry,
with a range of applications including mental health and
psychological therapies, pain management, and robotic surgery.
Glimpse, through its base of subsidiary companies, has direct
experience in developing such solutions with leading companies,
hospitals, and universities in the segment. We look forward to our
collaboration with Pasithea."
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology
company focused on the research and discovery of new and effective
treatments for psychiatric and neurological disorders. With an
experienced team of experts in the fields of neuroscience and
psychopharmacology, Pasithea is developing new molecular entities
for the treatment of psychiatric and neurological disorders.
Pasithea is also focused on addressing the needs of patients
currently suffering with mental illness by providing access to IV
ketamine infusions both in clinics and in-home settings.
About The Glimpse Group,
Inc.
The Glimpse Group (Nasdaq: VRAR, FSE:9DR) is a Virtual and
Augmented Reality platform company, comprised of multiple VR and AR
software & services companies, and designed with the specific
purpose of cultivating entrepreneurs in the VR/AR industry.
Glimpse's unique business model simplifies challenges faced by
VR/AR entrepreneurs and creates a robust ecosystem, while
simultaneously providing investors an opportunity to invest
directly into the emerging VR/AR industry via a diversified
platform. For more information on The Glimpse Group, please
visit www.theglimpsegroup.com
Foretell Reality, a fully owned Glimpse Group subsidiary,
leverages the unique capabilities of VR technology to enhance human
interaction and applies it to various uses cases of mental health
therapy, support, and soft skills training. For more
information on Foretell Reality, please visit
www.foretellreality.com
Forward Looking
Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp.
Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp.
Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
The Glimpse Group
Contact:
Maydan Rothblum
CFO & COO
The Glimpse Group, Inc.
917-292-2685
maydan@theglimpsegroup.com